When Grantham Rings the Alarm Bell
If he is right, my portfolio is exactly where the damage would happen. Here is how I thought it through.
-
-
Did I Mistake an Ethereum Thesis for a Crypto Thesis?
I believed the macro thesis behind my crypto position more than ever. I just stopped believing in the assets I chose to express it. Nine months in, here’s the gap I didn’t see coming.”
-
May 2026 Portfolio Review: China Is Dragging Everything Down
May 2026 portfolio review is up. The headline +0.4% hides a tale of two portfolios — non-China up +28% YTD, China down -15.2%. I break down what’s dragging, why I’m still holding the AV names, and what I’m doing in June ahead of the FOMC on June 17.
-
The SpaceX IPO: One Frontier Bet Is Enough
Excerpt (for WordPress post listing/preview):
The SpaceX IPO is the biggest market event of 2026. At $1.77 trillion and 110x trailing revenue, everyone wants a piece. I don’t — at least not at this price. Here’s why I’m sitting out SPCX, what the RKLB hype trade tells us about sentiment-driven investing, and why I’m watching ATI and Honeywell instead. Plus: what Quantinuum’s quiet Nasdaq debut says about where the real value is hiding while everyone watches the rocket. -
Singapore and Hong Kong as Safe Havens — Where Is Capital Flowing in 2026?
As a Singaporean investor who largely ignored SGX for years, I didn’t expect to be writing about Singapore as a global safe haven. But the data is hard to ignore — and the capital flows from Dubai, Hong Kong, and beyond are reshaping two markets worth paying attention to.
-
Doximity (NYSE:DOCS): The Pharma Platform I’m Still Sitting With — But Not Comfortably
Doximity has been sitting in my portfolio under “healthcare drag” for too long without a proper post. After digging into it properly, the business model is more interesting — and more complicated — than most coverage suggests. Here’s my honest breakdown of what’s keeping me in, what worries me about the management, and what May 13 needs to show me.
-
My China Stocks: Ground-Level Reality vs What the Market Is Pricing
I was in Beijing when China’s Q1 GDP came in at 5.0%. The number and what I saw on the ground didn’t quite tell the same story. Here’s how my China positions benchmarked against HSCI — and what I’m watching next.
-
The Iran War, My Portfolio, and Why I’m Considering Honeywell
Five weeks into the Iran war, the Strait of Hormuz is still largely shut and markets are feeling it. Here’s how I’m thinking about my portfolio — why I’m trimming ALB and exiting NOG, and why Honeywell (HON) is the stock I’m watching closely for 2026.
-
LEAPS: Why I’m Buying Time Instead of Stocks
Start of 2026 I was feeling pretty good about tech. Then the Iran war started and changed the mood a bit. Instead of buying shares outright in GOOGL, AMZN and PLTR, I bought LEAPS — long-dated call options that give me the same directional exposure for $85,206 less capital, with my downside capped at the $28,155 premium paid.
-
February 2026 Portfolio Performance: When the Plan Gets Tested
February was rough — my equities portfolio ended down 3.7% while the S&P 500 dropped 0.9%. A war in the Middle East, an AI wave gutting SaaS valuations, and inflation refusing to cooperate. Not exactly the month anyone planned for. But YTD I’m still up 4.0%, and the 2026 strategy is intact. Here’s what happened, what hurt, and what I’m doing about it.